ArticleTherapeutic advances in medical oncology2025
The predictive value of the systemic inflammation-nutrition index for treatment response and prognosis in patients with locally advanced gastrointestinal stromal tumors receiving neoadjuvant imatinib therapy: a dual-center retrospective cohort study.
Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although systemic inflammation- and nutrition-related indices have demonstrated predictive value for treatment response and prognosis in various malignancies, their role in locally advanced gastrointestinal stromal tumors (LA-GIST) undergoing neoadjuvant imatinib therapy (NIT) remains unclear. Objectives: To evaluate the predictive value of the Systemic Inflammation-Nutrition Index (SINI) for pathological response and prognosis in patients with LA-GIST receiving NIT. Designs: A retrospective, two-center study was conducted to evaluate the prognostic value of high pathological response, and to develop a nomogram incorporating SINI for predicting high pathological response in patients with LA-GIST undergoing NIT. Methods: A retrospective analysis was performed on 200 patients with LA-GIST receiving NIT. Least Absolute Shrinkage and Selection Operator regression was used to construct the SINI from key hematological markers and to evaluate its association with relapse-free survival (RFS). A nomogram for predicting high response was established based on independent predictors identified by multivariate analysis, and the performance and prognostic values were validated in an external cohort. Results: High response was independently associated with improved 5-year RFS. The 5-year RFS showed a significant stepwise gradient across the low-, medium-, and high-SINI groups (46.0% vs 75.3% vs 94.8%, all Conclusion: The SINI is an effective predictor of pathological response and prognosis in LA-GIST patients receiving NIT. The validated nomogram offers a practical tool for individualized treatment decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.